News | News By Subject | News by Disease News By Date | Search News

Hepatitis-B News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Reeling From GlobeImmune (GBIM) Hepatitis B Termination, Gilead (GILD) Faces Merck & Co. (MRK), GlaxoSmithKline (GSK) Competition     11/22/2016
Bay Area's Dynavax (DVAX) Plunges After the FDA Spurns HEPLISAV-B Again     11/14/2016
The $40 Billion NASH Market and the 3 Biotechs That Stand to Profit From it     11/2/2016
Bay Area's Dynavax (DVAX) Plummeted After the FDA Cancels Advisory Meeting     9/6/2016
Roche (RHHBY) Terminates Deal with Inovio Pharma (INO), Inovio to Develop Hep B Immunotherapy Solo     8/3/2016
Dynavax (DVAX)'s Possible Hep B Win Could Prove a Threat to GlaxoSmithKline (GSK)     5/3/2016
FDA Pushes Back PDUFA Date for Dynavax (DVAX)'s Hep B Vaccine HEPLISAV-B     4/27/2016
Gilead (GILD)'s Hep B Candidate Delivers in Two Late-Stage Studies     4/15/2016
Alnylam (ALNY)’s John Maraganore Provides Leadership for RNAi Development and Biotech Industry     4/4/2016
ContraVir's CMX157 Bests Gilead (GILD)'s Tenofovir AF (TAF) Against Hep B Virus in Head-to-Head In-Vitro Study     3/29/2016
Benitec (BLT.AX)'s Hepatitis B Therapy Reduces HBV DNA By 98.5% in Early Study     3/8/2016
Dynavax (DVAX) Surges as Hep B Vaccine Meets Goals in Phase III Study     1/7/2016
Tekmira (TKMR) Changes Name to Arbutus Biopharma, Kills Ebola Program and Focuses on Hepatitis B     7/22/2015
Gilead (GILD)’s Hep B Trial Failure Will Inspire M&A Activity, Say Analysts     5/29/2015
Gilead (GILD), GlobeImmune (GBIM)'s Hep B Drug Flunks Phase II Study     5/27/2015

News from Around the Web
Some Vaccines Tied to Lower Kids' Leukemia Risk, Baylor College of Medicine Study     2/3/2011
Focusing HIV Treatment Helps Control Concurrent Hepatitis B Infection, Wake Forest University School of Medicine Study     7/15/2009
Experts Identify Mutant Genes Linked To Hepatitis B, University of Tokyo Study     4/7/2009
Hepatitis B Vaccine Protection May Wane In Teens, Centers for Disease Control and Prevention (CDC) Study     10/24/2008
Hepatitis B Vaccine Not Associated with Multiple Sclerosis, University of Paris Study     9/30/2008
Researchers at The Wistar Institute Invigorate 'Exhausted' Immune Cells     9/19/2008
Hepatitis B Genotypes And Mutants May Influence Liver Cancer Risk, Journal of the National Cancer Institute     8/15/2008
Structure of Hepatitis B Mapped by Spraying Virus in Utrecht University Study     7/29/2008
FDA Seeks New Hepatitis Blood Donation Rules     5/21/2008
Hepatitis B Virus Triggers Cell 'Suicide' In Patients With Chronic Infection, University College London Study     4/9/2008
New Drug Found Better at Suppressing Hep B Virus     1/3/2008
Stanford University School of Medicine Researchers Find Way to Fight Treacherous Hepatitis B     10/2/2007
Korean Mummies May Provide Clues to Combat Hepatitis B, Hebrew University of Jerusalem Study     7/25/2007
Hepatitis B Drug Can Compromise HIV Treatment     6/21/2007
Sweat May Pass on Hepatitis B in Contact Sports     3/1/2007

Press Releases
Assembly Biosciences (ASMB) Announces Successful Completion Of ABI-H0731 Phase Ia Trial And Upcoming Conference Presentations     2/16/2017
Quest Diagnostics (DGX) Release: Company Launches Nation's First Hepatitis B Virus Quantitative Test To Help Assess Response To Antiviral Therapy     1/18/2017
GeoVax Labs Inc. (GOVX.OB) Release: Company To Collaborate With Georgia State University On Development Of Therapeutic Hepatitis B Vaccine     1/17/2017
European Commission (EC) Grants Marketing Authorization For Gilead (GILD)’s Vemlidy (Tenofovir Alafenamide, TAF) For The Treatment Of Chronic Hepatitis B Virus Infection     1/11/2017
ContraVir Awarded Grant From Canada's National Research Council To Advance CRV431 For The Treatment Of Hepatitis B     1/3/2017
Benitec (BLT.AX) Releases Pivotal Data In An In Vivo Hepatitis B Model     12/20/2016
Benitec (BLT.AX) Announces Positive Data For Its Hepatitis B Virus Program     12/20/2016
Japan’s Ministry of Health, Labour And Welfare Approves Gilead (GILD)’s Vemlidy For Patients With Chronic Hepatitis B Virus Infection     12/19/2016
ContraVir Expands Phase 2a Trial Of Tenofovir Exalidex (Formerly CMX157) To Include Doses Above 100 Mg     12/19/2016
Poxel SAS Announces Phase 1 Initiation Of EYP001 For The Treatment Of Chronic Hepatitis B Virus Infection By Licensing Partner Enyo Pharma     12/19/2016
Enyo Pharma Announces Successful Initiation Of The Phase 1 Clinical Programme With EYP001, Its Lead Candidate For The Treatment Of Chronic Hepatitis B Virus Infection     12/16/2016
Arbutus Biopharma (ABUS) Provides Additional Data From The ARB-1467 Phase II Clinical Trial In HBV Patients     12/13/2016
ContraVir's Cyclophilin Inhibitor CRV431 Potently Inhibits Essential Pathway In Hepatitis B     12/8/2016
Health Canada Release: Information Update - Direct-Acting Antivirals, Used For Hepatitis C, May Reactivate Hepatitis B     12/2/2016
AiCuris Announces U.S. NIH Support Of Preclinical Study With AIC649 Against Chronic Hepatitis B     11/23/2016

//-->